Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px
Document › Details

Cellectis S.A.. (9/4/14). "Press Release: Cellectis Announces the Closing of the Sale of Its Swedish Subsidiary Cellectis AB to Takara Bio Inc.". Paris.

Organisations Organisation Cellectis S.A. (Euronext Growth: ALCLS, Nasdaq: CLLS)
  Group Cellectis (Group)
  Organisation 2 Takara Bio Inc.
  Group Takara Shuzo (Group)
Products Product stem cell therapy
  Product 2 Chimeric Antigen Receptor T-Cell therapy (CAR-T therapy)
Index term Index term Cellectis–Takara Shuzo: investment, 201407–201409 acquisition €na of Cellectis AB by Takara Bio Inc
Person Person Valachs, Philippe (Cellectis 201110– General Secretary)
     


Cellectis (Alternext: ALCLS.PA) a leader in the development of adoptive immunotherapies based on engineered allogeneic CART cells (UCART) today announces that it has closed the sale of its subsidiary Cellectis AB to Takara Bio Inc.

The financials terms have not been disclosed.

The Company now concentrates its activities in the field of oncology through the development of Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy products generated through its allogeneic CAR-T platform, both on its own as well as in partnership with Servier and Pfizer.


About Cellectis

Cellectis is a biopharmaceutical company focused on oncology. The company’s mission is to develop a novel generation of therapy based on engineered T-cells to treat cancer. Cellectis capitalizes on its 14 years of expertise in genome engineering, based on TALEN™, meganucleases and the state-of-the-art electroporation technology Pulse Agile, to create a new generation of cancer immunotherapy for treating leukemias and solid tumors. Cellectis adoptive cancer immunotherapy for chronic and acute leukemias is based on the first allogeneic T-cell chimeric antigen receptor (CAR) technology. CAR technologies are designed to target surface antigens expressed on cells. These treatments reduce toxicities associated with current chemotherapeutics and have the potential for curative therapy. The Cellectis Group is focused on life sciences and uses leading genome engineering technologies to build innovative products in various fields and markets. Cellectis is listed on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com


For more information, please contact:

Cellectis
Philippe Valachs
Phone: +33 (0)1 81 69 16 00
e-mail: media@cellectis.com


Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company’s objectives based on the current expectations and assumptions of the Company’s management only and involve unforeseeable risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements.

   
Record changed: 2019-06-09

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for Cellectis (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioPharm America 2019 Boston September 600x60px




» top